Ramep 20 mg 28 tablets

Product description: each stomach-resistant tablet contains 20 mg of Rabeprazole sodium. Acid suppressant for the stomach. Usage instructions: once daily: Ramip tablets should be taken in the morning before eating. Although it has not been proven that the time of day or food intake has any effect on the activity of sodium Rabeprazole, this schedule will facilitate adherence to the treatment. Adults / Elderly. Zollinger-Ellison syndrome: the recommended initial dose for adults is 60 mg once daily. The dose can be adjusted to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day can be given. A dose of 120 mg may require divided doses, 60 mg twice daily. Treatment should continue as long as clinically indicated. Pyloric ulcer resection: patients with Helicobacter pylori infection should be treated with eradication therapy. The following regimen is recommended for 7 days. Rabep 20 mg twice daily + Clarithromycin 500 mg twice daily and Amoxicillin 1 g twice daily. Warnings and precautions: the symptomatic response to treatment with Rabeprazole sodium does not exclude the presence of gastric or esophageal malignancy, so the possibility of malignancy should be ruled out before starting Ramip therapy. Ramip should not be used in patients with known hypersensitivity to the active substance or any of the excipients. Ramip is not used during pregnancy or breastfeeding. Patients on long-term therapy (especially those treated for more than a year) should be under regular monitoring. Cross hypersensitivity reactions with other proton pump inhibitors or alternative benzodiazepines cannot be excluded. Patients should be warned not to chew or crush Ramip tablets, but to swallow them whole. Post-marketing reports have indicated blood disorders (thrombocytopenia and neutropenia). In most cases where no alternative causative factors could be identified, events were uncomplicated and resolved upon discontinuation of Rabeprazole. Concurrent administration of Atazanavir with Ramip is not recommended. Proton pump inhibitors, including Ramip, may increase the risk of gastrointestinal infections such as Salmonella, Shigella, and Clostridium difficile. Proton pump inhibitors, especially if used at high doses and for long periods (>1 year), may slightly increase the risk of fractures of the hip, wrist, and spine, particularly in the elderly or those with other known risk factors. Magnesium deficiency: severe hypomagnesemia has been reported in patients treated with PPIs like Rabeprazole sodium for at least three months, and in most cases for a year. Serious manifestations of magnesium deficiency such as fatigue, seizures, delirium, cramps, dizziness, ventricular arrhythmias may occur, but they may start insidiously and be overlooked. Most affected patients improve after magnesium replacement and discontinuation of PPIs. Concurrent use of Rabeprazole with Methotrexate: literature indicates that the concurrent use of PPIs with Methotrexate (primarily at high doses; see Methotrexate description) may elevate and prolong blood levels of Methotrexate and/or its metabolites, potentially leading to Methotrexate toxicity. In cases of high-dose Methotrexate, temporary withdrawal of PPIs may be considered for some patients. Effect on Vitamin B12 absorption: Rabeprazole sodium, like all antacids, may reduce the absorption of vitamin B12 (cyanocobalamin) due to decreased chloride or deficiency. This should be considered in patients with low body stores or risk factors for decreased B12 absorption during long-term therapy or if related clinical symptoms are observed. Subacute Cutaneous Lupus Erythematosus (SCLE): Proton pump inhibitors are very rarely associated with SCLE. If lesions occur, especially on sun-exposed skin, and are accompanied by joint pain, the patient should seek medical help immediately and the healthcare provider should consider stopping Ramip. Treatment of SCLE after previous PPI therapy may increase the risk of SCLE with other PPIs. Renal failure: acute interstitial nephritis (AIN) has been observed in patients taking Rabeprazole and can occur at any time during treatment. Laboratory test interference: increased levels of Chromogranin A (CgA) may interfere with investigations for neuroendocrine tumors. To avoid this interference, Ramep treatment should be stopped at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels do not return to reference ranges after the initial measurement, repeat measurements should be taken 14 days after stopping PPI therapy. Components: each stomach-resistant tablet contains 20 mg of Rabeprazole sodium. Product details: Brand: Ramep. Quantity: 28 tablets. Product model: Tablets. Product type: Tablets.